Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy

Phase 2TerminatedNCT02362230

Sun Yat-sen University26 enrolled

Overview

Evaluating the safety and efficacy of Icotinib administered in 2-month treatments, in patients with metastatic triple-negative breast cancer that have received at least two prior treatments.

This is a phase II, multi-center study. Sixty-seven patients are planned to be enrolled. All patients will receive Icotinib 125 mg BID administered for 8 weeks. Patients with a complete response, partial response or stable disease at that time may continue to be treated based on physician discretion. Follow up is then required until resolution or stabilization of any treatment-related toxicity, and patients with stable disease or objective responses must also continue evaluations until survived.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Breast Cancer

Interventions

IcotinibDRUG

Icotinib 125 mg BID

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 years or older * ECOG 0 or 1 * Primary or metastatic tumor onfirmed as triple negative * Measurable disease per RECIST version 1.1 * normal organ function, including bone marrow function, renal function, liver function, and cardiac function * Two or more prior chemotherapy * signed and dated an informed consent form * Life expectancy of at least 12 weeks Exclusion Criteria: * Pregnant or breast feeding * ECOG score ≧2 * Uncontrolled medical problems * Hepatic, renal, or bone marrow dysfunction as detailed above * Concurrent malignancy or history of other malignancy within the last five years except as noted above * Patients were unable or unwilling to comply with program requirements

Locations (1)

Sun Yat-sen University, Cancer Center

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

Progression Free Survival

the time from randomization to the date of disease progression or death from any causes

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.